Home    >    Press Releases    >    Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD)

Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD)

Euthymics Bioscience, Inc. today announced that it has initiated a Phase 1 clinical trial of EB-1020, a next-generation drug in development for treating adult attention deficit hyperactivity disorder (ADHD), with low risk of drug abuse liability.

 

Press Release-EB-1020_Phase1_FINAL2